N° (%) | |
---|---|
386 | |
Age (years) | |
Median | 68 |
Range | 21–88 |
Elderly (≥ 70) | 170 (44) |
Sex | |
Male | 260 (67.4) |
Female | 126 (32.6) |
ECOG PS | |
0–1 | 338 (87.6) |
≥ 2 | 48 (12.4) |
Primary tumor | |
NSCLC | 156 (40.4) |
Melanoma | 163 (42.2) |
Renal cell carcinoma | 59 (15.3) |
Others | 8 (2.1) |
No. of metastatic sites | |
≤ 2 | 219 (56.7) |
> 2 | 167 (43.3) |
Type of anti-PD-1/PD-L1 agent | |
Pembrolizumab | 120 (31.1) |
Nivolumab | 253 (65.5) |
Atezolizumab | 10 (2.6) |
Others | 3 (0.8) |
Treatment line of immunotherapy | |
First | 137 (35.5) |
Non-first | 249 (64.5) |